Importantly, different clinical trials in adult and pediatric tumor patients are ongoing to prove the safety and efficacy of targeting B7-H3 using CAR-engineered cells or humanized antibodies conjugated or not with tumoricidal compounds (https://www.clinicaltrials.gov (accessed on 3 August 2022)). This evidence concerns the gene CD276 and neoplasm.